Table 4. Univariate analyses of the factors correlated with HBV virological response and reactivation of HBV.

	HBV DNA detection status (n,%)		P-value
Patients with detectable serum HBV-DNA levels pretreatment (n=67)
Posttreatment follow-up evaluation	HBV-DNA(+)	HBV-DNA(-)※
rs8099917 genotype
TT	16(42.1%)	22(57.9%)	0.029
TG+GG	20(69.0%)	9(31.0%)
HBeAg state
HBeAg Positive	17(89.5%)	2(10.5%)	0.039
HBeAg negative	30(62.5%)	18(37.5%)
HBV genotype
B	19(59.4%)	13(40.6%)	0.187
C	27(77.1%)	8(22.9%)
Patients with undetectable serum HBV-DNA levels pretreatment (n=79)
Posttreatment follow-up evaluation	HBV-DNA(+)#	HBV-DNA(-)
rs8099917 genotype
TT	6(13.9%)	37(86.1%)	0.005
TG+GG	15(41.7%)	21(58.3%)
HBeAg state
HBeAg Positive	10(55.6%)	8(44.4%)	0.017
HBeAg negative	14(22.9%)	47(77.1%)
HBV genotype
B	12(44.4%)	15(55.6%)	0.390
C	21(55.3%)	17(44.7%)

+ HBV DNA detectable by a real-time PCR ( ≥200 IU/mL).

HBV DNA not detectable by a real-time PCR (≤200 IU/mL).

^※HBV virologic response was defined as a reduction of serum HBV-DNA level to 200 IU/mL at the end of treatment in those with detectable serum HBV-DNA levels pretreatment;

^#HBV virologic reappearance was defined as an increase of posttreatment serum HBV-DNA levels to 200 IU/mL in those with pretreatment undetectable serum HBV-DNA levels.